Showing 521-530 of 3456 results for "".
Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.Targeting Cellulite: Evolving Approaches
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/targeting-cellulite-evolving-approaches/23796/New treatments mean that dermatologists can improve treatment outcomes for the 90% of women who have cellulite.New Frontiers in Skin Cancer Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-frontiers-in-skin-cancer-management/57249/Across the spectrum of diagnosis, prognostication, prevention, and treatment, advances in technology and therapeutics are reshaping how clinicians care for patients with skin cancer. This issue highlights innovations and insights that are changing the field and offers a glimpse of where skin cancerWarts and All: A Treatment Update for Verruca Vulgaris
https://practicaldermatology.com/topics/general-topics/warts-and-all-a-treatment-update-for-verruca-vulgaris/21451/"Psleep": Psoriasis and Sleep
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/psleep-psoriasis-and-sleep/29075/The “invisible” impacts of psoriasis are those not directly seen on examination. These include itch, pain, fatigue and sleep dysfunction, which may be improved by our systemic therapies. However, there is a gap between the patients’ reporting of these experienced invisible impacts and their physiciaInvestigational Oral Treatments for Psoriasis: A Review of Phase 2 and 3 Trials
https://practicaldermatology.com/topics/psoriasis/investigational-oral-treatments-for-psoriasis-a-review-of-phase-2-and-3-trials/23318/Although biologic medications have proven to be highly effective in the treatment of psoriasis, there remains a need for oral medications that offer similar success rates. Here’s a look in the pipeline.Verrucous Psoriasis
https://practicaldermatology.com/topics/psoriasis/verrucous-psoriasis/27148/Verrucous psoriasis (VP) is a rare subtype of psoriasis most commonly affecting middle-aged to older adults, with fewer than 35 reported cases within the current literature. It is characterized by symmetric wart-like, hyperkeratotic, papillomatous plaques. Treatment options are limited and variable,A Nose for Disease: A Review of Olfactory-Based Diagnosis in Dermatology
https://practicaldermatology.com/topics/infections-infectious-disease/a-nose-for-disease-a-review-of-olfactory-based-diagnosis-in-dermatology/23650/Despite technological advancements in diagnosis, the sense of smell can still be a helpful tool in the medical clinic.Treatment Guidelines for the PicoWay® Laser System in Skin of Color
https://practicaldermatology.com/topics/general-topics/treatment-guidelines-for-the-picoway-laser-system-in-skin-of-color/22087/Picosecond laser therapy for benign pigmented lesionsThe Future of Atopic Dermatitis Therapy
https://practicaldermatology.com/topics/general-topics/the-future-of-atopic-dermatitis-therapy/21143/As new research elucidates the individual mechanisms of atopic dermatitis, the development of therapies that more directly influence the disease may change the scope of treatment.